Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non-Small-Cell Lung Cancer in the First-Line Setting?

J Clin Oncol. 2020 Mar 10;38(8):843-844. doi: 10.1200/JCO.19.02509. Epub 2020 Jan 2.

Authors

Tomohiro Tanaka¹, Hiroto Ishiki¹, Emi Kubo¹, Sayuri Yokota¹, Masaki Shimizu¹, Daisuke Kiuchi¹, Eriko Satomi¹

Affiliation

¹ Tomohiro Tanaka, MD, PhD, Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; and Hiroto Ishiki, MD; Emi Kubo, MD, PhD; Sayuri Yokota, MD; Masaki Shimizu, MD; Daisuke Kiuchi, MD; and Eriko Satomi, MD, Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.

PMID: 31895605
DOI: 10.1200/JCO.19.02509

No abstract available

Publication types

Letter
Comment

MeSH terms

Acrylamides
Aniline Compounds
Carboplatin
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
Gefitinib
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Pemetrexed
Platinum

Substances

Acrylamides
Aniline Compounds
Pemetrexed
osimertinib
Platinum
Carboplatin
EGFR protein, human
ErbB Receptors
Gefitinib